Search

EP-4741392-A1 - 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF

EP4741392A1EP 4741392 A1EP4741392 A1EP 4741392A1EP-4741392-A1

Abstract

The present invention relates to a compound as represented by formula (A), or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and a pharmaceutical composition thereof and the use thereof in the treatment and/or prevention of diseases mediated by a wild-type and/or mutated BTK.

Inventors

  • WANG, YIHAN
  • LI, Huanyin
  • AI, Yixin

Assignees

  • Shenzhen TargetRx Co., Ltd.

Dates

Publication Date
20260513
Application Date
20240702

Claims (20)

  1. A compound of formula (A), or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof: wherein, ring A is a benzene ring or a 5- to 6-membered heteroaromatic ring; X 1 is N, CD or CH; X 2 is N or CR 2 ; R 1 is H, D, halogen, -C(O)R a , -C(O)OR a , -C(O)NR b R c , -NR b R c , -NR a C(O)R b , -NR a C(O)OR b , -NR a C(O)NR b R c , -OR a , -OC(O)R a , -OC(O)NR b R c , -NR a S(O) 2 R b , -S(O) 2 NR b R c , -S(O)R a , -S(O) 2 R a , -P(=O)R b R c , -OP(=O)R b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 12-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 12-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R; wherein each of R a , R b and R c is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R b , R c and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R; R 2 is H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 12-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 12-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R'; R 3 and R 4 are independently H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R 5 is halogen; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R s and R t are independently H, D, halogen, -OR a , -NR b R c , C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; each R is independently: 1) H, D, halogen, oxo, -C(O)R a , -C(O)OR a , -C(O)NR e R f , -NR e R f , -NR d C(O)R e , -NR d C(O)OR e , - NR d C(O)NR e R f , -OR a , -OC(O)R d , -OC(O)NR e R f , -NR d S(O) 2 R e , -S(O) 2 NR e R f , -S(O)R d , -S(O) 2 R d , - P(=O)R e R f , -OP(=O)R e R f ; or 2) C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, -C 1-6 alkylene-C 3-6 cycloalkyl, - C 1-6 alkylene-3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; or 3) two R on the same atom or on two adjacent atoms are taken together with the atom(s) to which they are attached to form C 3-6 cycloalkyl, 3- to 12-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; each R' is independently H, D, halogen, oxo, -C(O)R d , -C(O)OR d , -C(O)NR e R f , -NR e R f , -NR d C(O)R e , - NR d C(O)OR e , -NR d C(O)NR e R f , -OR a , -OC(O)R d , -OC(O)NR e R f , -NR d S(O) 2 R e , -S(O) 2 NR e R f , -S(O)R d , - S(O) 2 R d , -P(=O)R e R f , -OP(=O)R e R f ; C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or two R' on the same atom or on two adjacent atoms are taken together with the atom(s) to which they are attached to form C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R"; wherein each of R d , R e and R f is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R e , R f and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R"; each R" is independently H, D, halogen, oxo, -C(O)R g , -C(O)OR g , -C(O)NR h R j , -NR h R j , -NR g C(O)R h , - NR g C(O)OR h , -NR g C(O)NR h R j , -OR g , -OC(O)R g , -OC(O)NR h R j , -NR g S(O) 2 R h , -S(O) 2 NR h R j , -S(O)R g , - S(O) 2 R g , -P(=O)R h R j , -OP(=O)R h R j , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or two R" on the same atom or on two adjacent atoms are taken together with the atom(s) to which they are attached to form C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R‴; each R‴ is independently H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 6-10 aryl or 5-to 10-membered heteroaryl; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R h , R j and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more D, up to fully deuterated.
  2. A compound of formula (I), or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof: wherein, X 1 is N, CD or CH; X 2 is N or CR 2 ; R 1 is H, D, halogen, -C(O)R a , -C(O)OR a , -C(O)NR b R c , -NR b R c , -NR a C(O)R b , -NR a C(O)OR b , -NR a C(O)NR b R c , -OR a , -OC(O)R a , -OC(O)NR b R c , -NR a S(O) 2 R b , -S(O) 2 NR b R c , -S(O)R a , -S(O) 2 R a , -P(=O)R b R c , -OP(=O)R b R c , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 12-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 12-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R; wherein each of R a , R b and R c is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R b , R c and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R; R 2 is H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 12-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 12-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R'; R 3 and R 4 are independently H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R 5 is halogen; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R s and Rt are independently H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; each R is independently: 1) H, D, halogen, oxo, -C(O)R a , -C(O)OR a , -C(O)NR e R f , -NR e R f , -NR d C(O)R e , -NR d C(O)OR e , - NR d C(O)NR e R f , -OR a , -OC(O)R d , -OC(O)NR e R f , -NR d S(O) 2 R e , -S(O) 2 NR e R f , -S(O)R d , -S(O) 2 R d , - P(=O)R e R f , -OP(=O)R e R f ; or 2) C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; or 3) two R on the same atom or on two adjacent atoms are taken together with the atom(s) to which they are attached to form C 3-6 cycloalkyl, 3- to 12-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; each R' is independently H, D, halogen, oxo, -C(O)R d , -C(O)OR d , -C(O)NR e R f , -NR e R f , -NR d C(O)R e , - NR d C(O)OR e , -NR d C(O)NR e R f , -OR a , -OC(O)R d , -OC(O)NR e R f , -NR d S(O) 2 R e , -S(O) 2 NR e R f , -S(O)R d , - S(O) 2 R d , -P(=O)R e R f , -OP(=O)R e R f ; C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or two R' on the same atom or on two adjacent atoms are taken together with the atom(s) to which they are attached to form C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R"; wherein each of R d , R e and R f is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R e , R f and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R"; each R" is independently H, D, halogen, oxo, -C(O)R g , -C(O)OR g , -C(O)NR h R j , -NR h R j , -NR g C(O)R h , - NR g C(O)OR h , -NR g C(O)NR h R j , -OR g , -OC(O)R g , -OC(O)NR h R j , -NR g S(O) 2 R h , -S(O) 2 NR h R j , -S(O)R g , - S(O) 2 R g , -P(=O)R h R j , -OP(=O)R h R j , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or two R" on the same atom or on two adjacent atoms are taken together with the atom(s) to which they are attached to form C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R h , R j and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more D, up to fully deuterated.
  3. The compound according to claim 1 or 2, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein R 1 is H, D, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R; alternatively, R 1 is H, D, wherein the above groups are optionally substituted with one or more R; alternatively, R 1 is wherein the above groups are optionally substituted with one or more R; alternatively, R 1 is wherein the above groups are optionally substituted with one or more R; alternatively, R 1 is H.
  4. The compound according to any one of claims 1 to 3, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein R 2 is H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered monocyclic heterocyclyl, 6- to 12-membered fused bicyclic heterocycle, 7- to 10-membered spiro heterocycle, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered monocyclic heterocyclyl, 6- to 12-membered fused bicyclic heterocycle, 7- to 10-membered spiro heterocycle, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R'; alternatively, R 2 is H, D, halogen, methyl, -CHF 2 , ethyl, isopropyl, wherein the above groups are optionally substituted with one or more D, up to fully deuterated; alternatively, R 2 is H, D, halogen, methyl, -CHF 2 , ethyl, isopropyl, wherein the above groups are optionally substituted with one or more D, up to fully deuterated; alternatively, R 2 is H, D, methyl, -CHF 2 , wherein the above groups are optionally substituted with one or more D, up to fully deuterated; alternatively, R 2 is H, D, -CHF 2 or wherein the above groups are optionally substituted with one or more D, up to fully deuterated; alternatively, R 2 is H or D; alternatively, R 2 is -CHF 2 or wherein the above groups are optionally substituted with one or more D, up to fully deuterated; alternatively, R 2 is wherein the above group is optionally substituted with one or more D, up to fully deuterated.
  5. The compound according to any one of claims 1 to 4, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein Rs is F.
  6. The compound according to any one of claims 1 to 5, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein R 6 is methyl or -CD 3 .
  7. The compound according to claim 1 or 2, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein the compound is a compound of formula (II): wherein, X 2 is N or CR 2 ; R 2 is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R 5 is halogen; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; Rt is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; Y 1 is N or CR 12 ; R 10 , R 11 and R 12 are independently: 1) H, D, halogen, oxo, -C(O)R a , -C(O)OR a , -C(O)NR e R f , -NR e R f , -NR d C(O)R e , -NR d C(O)OR e , - NR d C(O)NR e R f , -OR a , -OC(O)R d , -OC(O)NR e R f , -NR d S(O) 2 R e , -S(O) 2 NR e R f , -S(O)R d , -S(O) 2 R d , - P(=O)R e R f , -OP(=O)R e R f ; or 2) C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; or 3) R 11 , R 12 and the atom to which they are attached are taken together to form C 3-6 cycloalkyl, which is optionally substituted with one or more R"; or 4) R 10 and R 11 or R 11 and R 12 and the atom to which they are attached are taken together to form 3- to 12-membered heterocyclyl or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; or 5) R 11 , R 12 and the atom to which they are attached are taken together to form C 6-10 aryl, which is optionally substituted with one or more R"; wherein each of R d , R e and R f is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R e , R f and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R"; each R" is independently H, D, halogen, oxo, -C(O)R g , -C(O)OR g , -C(O)NR h R j , -NR h R j , -NR g C(O)R h , - NR g C(O)OR h , -NR g C(O)NR h R j , -OR g , -OC(O)R g , -OC(O)NR h R j , -NR g S(O) 2 R h , -S(O) 2 NR h R j , -S(O)R g , - S(O) 2 R g , -P(=O)R h R j , -OP(=O)R h R j , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or two R" on the same atom or on two adjacent atoms are taken together with the atom(s) to which they are attached to form C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R h , R j and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more D, up to fully deuterated.
  8. The compound according to claim 7, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein, X 2 is N or CR 2 ; R 2 is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R 5 is halogen; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; Rt is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; Y 1 is N or CR 12 ; R 10 is H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more R"; R 11 and R 12 are independently H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; or, R 11 , R 12 and the atom to which they are attached are taken together to form C 3-6 cycloalkyl, which is optionally substituted with one or more R"; or R 10 and R 11 or R 11 and R 12 and the atom to which they are attached are taken together to form 3- to 7-membered monocyclic heterocyclyl, 6- to 12-membered fused bicyclic heterocycle or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; or R 11 , R 12 and the atom to which they are attached are taken together to form C 6-10 aryl, which is optionally substituted with one or more R"; each R" is independently D, -C(O)OR g , -C(O)NR h R j , -NR g C(O)R h , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated.
  9. The compound according to claim 7 or 8, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein, X 2 is N or CR 2 ; R 2 is H, D or halogen; alternatively, R 2 is H, D or F; alternatively, R 2 is H; R 5 is halogen; alternatively, R 5 is F; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; alternatively, R 6 is methyl or -CD 3 ; R t is H, D or halogen; alternatively, R t is H, D or F; Y 1 is N or CR 12 ; R 10 is H, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more R"; alternatively, R 10 is H, C 1-3 alkyl or C 1-3 haloalkyl, wherein the C 1-3 alkyl and C 1-3 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R 11 and R 12 are independently H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; alternatively, R 11 and R 12 are independently H or D; or, R 11 , R 12 and the atom to which they are attached are taken together to form C 3-6 cycloalkyl, which is optionally substituted with one or more R"; alternatively, R 11 , R 12 and the atom to which they are attached are taken together to form cyclohexyl, which is optionally substituted with one or more R"; or R 10 and R 11 or R 11 and R 12 and the atom to which they are attached are taken together to form 3- to 7-membered monocyclic heterocyclyl, which is optionally substituted with one or more R"; alternatively, R 10 and R 11 or R 11 and R 12 and the atom to which they are attached are taken together to form 6-membered heterocyclyl having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 10 and R 11 or R 11 and R 12 and the atom to which they are attached are taken together to form 6- to 12-membered fused bicyclic heterocycle, which is optionally substituted with one or more R"; alternatively, R 10 and R 11 or R 11 and R 12 and the atom to which they are attached are taken together to form 8- to 10-membered fused bicyclic heterocycle having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 11 , R 12 and the atom to which they are attached are taken together to form C 6-10 aryl, which is optionally substituted with one or more R"; alternatively, R 11 , R 12 and the atom to which they are attached are taken together to form phenyl, which is optionally substituted with one or more R"; or R 10 and R 11 or R 11 and R 12 and the atom to which they are attached are taken together to form 5- to 10-membered heteroaryl, which is optionally substituted with one or more R"; alternatively, R 10 and R 11 or R 11 and R 12 and the atom to which they are attached are taken together to form 5-membered or 6-membered heteroaryl having 1 or 2 ring heteroatoms N, wherein the group is optionally substituted with one or more R"; each R" is independently D, -C(O)OR g , -C(O)NR h R j , -NR g C(O)R h , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more D, up to fully deuterated; alternatively, each R" is independently D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated.
  10. The compound according to claim 1 or 2, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein the compound is a compound of formula (II-1): wherein, R 5 is halogen; alternatively, R 5 is F; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with one or more D, up to fully deuterated; alternatively, R 6 is methyl or -CD 3 ; R t is H, D or halogen; alternatively, R t is H, D or F; Y 1 is N, CH or CD; R 10 , R 11 and the atom to which they are attached are taken together to form 3- to 7-membered monocyclic heterocyclyl, which is optionally substituted with one or more R"; alternatively, R 10 , R 11 and the atom to which they are attached are taken together to form 6-membered heterocyclyl having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 10 , R 11 and the atom to which they are attached are taken together to form 6- to 12-membered fused bicyclic heterocycle, which is optionally substituted with one or more R"; alternatively, R 10 , R 11 and the atom to which they are attached are taken together to form 8- to 10-membered fused bicyclic heterocycle having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 10 , R 11 and the atom to which they are attached are taken together to form 5- to 10-membered heteroaryl, which is optionally substituted with one or more R"; alternatively, R 10 , R 11 and the atom to which they are attached are taken together to form 6-membered heteroaryl having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; each R" is independently D, -C(O)OR g , -C(O)NR h R j , -NR g C(O)R h , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more D, up to fully deuterated; alternatively, each R" is independently D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated.
  11. The compound according to claim 10, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein, R 5 is F; R 6 is methyl or -CD 3 ; Rt is H, D or F; Y 1 is N, CH or CD; R 10 , R 11 and the atom to which they are attached are taken together to form the following groups: , wherein the groups are optionally substituted with one or more D, up to fully deuterated; alternatively, R 10 , R 11 and the atom to which they are attached are taken together to form the following groups: wherein the groups are optionally substituted with one or more D, up to fully deuterated.
  12. The compound according to claim 1 or 2, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein the compound is a compound of formula (III): wherein, X 2 is N or CR 2 ; R 2 is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R 5 is halogen; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; Rt is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R 13 , R 14 and R 15 are independently: 1) H, D, halogen, oxo, -C(O)R d , -C(O)OR d , -C(O)NR e R f , -NR e R f , -NR d C(O)R e , -NR d C(O)OR e , - NR d C(O)NR e R f , -OR d , -OC(O)R d , -OC(O)NR e R f , -NR d S(O) 2 R e , -S(O) 2 NR e R f , -S(O)R d , -S(O) 2 R d , - P(=O)R e R f , -OP(=O)R e R f ; or 2) C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; or 3) R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 3- to 12-membered heterocyclyl or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; wherein each of R d , R e and R f is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R e , R f and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R"; each R" is independently H, D, halogen, oxo, -C(O)R g , -C(O)OR g , -C(O)NR h R j , -NR h R j , -NR g C(O)R h , - NR g C(O)OR h , -NR g C(O)NR h R j , -OR g , -OC(O)R g , -OC(O)NR h R j , -NR g S(O) 2 R h , -S(O) 2 NR h R j , -S(O)R g , - S(O) 2 R g , -P(=O)R h R j , -OP(=O)R h R j , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or two R" on the same atom or on two adjacent atoms are taken together with the atom(s) to which they are attached to form C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R h , R j and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more D, up to fully deuterated.
  13. The compound according to claim 12, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein, X 2 is N or CR 2 ; R 2 is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R 5 is halogen; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; Rt is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R 13 is H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more R"; R 14 and R 15 are independently H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; or, R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 3- to 7-membered monocyclic heterocyclyl, 6- to 12-membered fused bicyclic heterocycle or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; each R" is independently D, -C(O)OR g , -C(O)NR h R j , -NR g C(O)R h , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated.
  14. The compound according to claim 12 or 13, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein, X 2 is N or CR 2 ; R 2 is H, D or halogen; alternatively, R 2 is H, D or F; alternatively, R 2 is H; R 5 is halogen; alternatively, R 5 is F; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with one or more D, up to fully deuterated; alternatively, R 6 is methyl or -CD 3 ; R t is H, D or halogen; alternatively, R t is H, D or F; R 13 is H, C 1-6 alkyl, C 1-6 haloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more R"; alternatively, R 13 is H, C 1-3 alkyl, C 1-3 haloalkyl or 6-membered heterocyclyl having 1 or 2 ring heteroatoms N, wherein the C 1-3 alkyl, C 1-3 haloalkyl and 6-membered heterocyclyl are optionally substituted with one or more R"; R 14 and R 15 are independently H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; alternatively, R 14 and R 15 are independently H or D; or, R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 3- to 7-membered monocyclic heterocyclyl, which is optionally substituted with one or more R"; alternatively, R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 6-membered heterocyclyl having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 6- to 12-membered fused bicyclic heterocycle, which is optionally substituted with one or more R"; alternatively, R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 8- to 10-membered fused bicyclic heterocycle having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 5- to 10-membered heteroaryl, which is optionally substituted with one or more R"; alternatively, R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 6-membered heteroaryl having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; each R" is independently D, -C(O)OR g , -C(O)NR h R j , -NR g C(O)R h , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more D, up to fully deuterated; alternatively, each R" is independently D, C 1-6 alkyl, C 1-6 haloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated.
  15. The compound according to claim 1 or 2, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein the compound is a compound of formula (III-1): wherein, R 5 is halogen; alternatively, R 5 is F; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with one or more D, up to fully deuterated; alternatively, R 6 is methyl or -CD 3 ; R t is H, D or halogen; alternatively, R t is H, D or F; R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 3- to 7-membered monocyclic heterocyclyl, which is optionally substituted with one or more R"; alternatively, R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 6-membered heterocyclyl having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 6- to 12-membered fused bicyclic heterocycle, which is optionally substituted with one or more R"; alternatively, R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 8- to 10-membered fused bicyclic heterocycle having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 5- to 10-membered heteroaryl, which is optionally substituted with one or more R"; alternatively, R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form 6-membered heteroaryl having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; each R" is independently D, -C(O)OR g , -C(O)NR h R j , -NR g C(O)R h , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more D, up to fully deuterated; alternatively, each R" is independently D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated.
  16. The compound according to claim 15, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein, R 5 is F; R 6 is methyl or -CD 3 ; Rt is H, D or F; R 13 and R 14 or R 13 and R 15 and the atom to which they are attached are taken together to form wherein the group is optionally substituted with one or more D, up to fully deuterated.
  17. The compound according to claim 1 or 2, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein the compound is a compound of formula (IV): wherein, X 2 is N or CR 2 ; R 2 is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R 5 is halogen; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; Rt is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; Y 2 is O or S; R 16 and R 17 are independently: 1) H, D, halogen, oxo, -C(O)R d , -C(O)OR d , -C(O)NR e R f , -NR e R f , -NR d C(O)R e , -NR d C(O)OR e , - NR d C(O)NR e R f , -OR d , -OC(O)R d , -OC(O)NR e R f , -NR d S(O) 2 R e , -S(O) 2 NR e R f , -S(O)R d , -S(O) 2 R d , - P(=O)R e R f , -OP(=O)R e R f ; or 2) C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; or 3) R 16 , R 17 and the atom to which they are attached are taken together to form C 3-6 cycloalkyl, 3- to 12-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the groups are optionally substituted with one or more R"; or wherein each of R d , R e and R f is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R e , R f and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more R"; each R" is independently H, D, halogen, oxo, -C(O)R g , -C(O)OR g , -C(O)NR h R j , -NR h R j , -NR g C(O)R h , - NR g C(O)OR h , -NR g C(O)NR h R j , -OR g , -OC(O)R g , -OC(O)NR h R j , -NR g S(O) 2 R h , -S(O) 2 NR h R j , -S(O)R g , - S(O) 2 R g , -P(=O)R h R j , -OP(=O)R h R j , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or two R" on the same atom or on two adjacent atoms are taken together with the atom(s) to which they are attached to form C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl or 5- to 10-membered heteroaryl, or R h , R j and the atom to which they are attached are taken together to form 3- to 7-membered heterocyclyl or 5- to 10-membered heteroaryl; wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 3- to 7-membered heterocyclyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more D, up to fully deuterated.
  18. The compound according to claim 17, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein, X 2 is N or CR 2 ; R 2 is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; R 5 is halogen; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; Rt is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; Y 2 is O or S; R 16 and R 17 are independently H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more R"; or, R 16 , R 17 and the atom to which they are attached are taken together to form C 3-6 cycloalkyl, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form 3- to 7-membered monocyclic heterocyclyl, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form 6- to 12-membered fused bicyclic heterocycle, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form C 6-10 aryl, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form 5- to 10-membered heteroaryl, which is optionally substituted with one or more R"; each R" is independently D, -C(O)OR g , -C(O)NR h R j , -NR g C(O)R h , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated.
  19. The compound according to claim 17 or 18, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein, X 2 is N or CR 2 ; R 2 is H, D or halogen; alternatively, R 2 is H, D or F; alternatively, R 2 is H; R 5 is halogen; alternatively, R 5 is F; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with one or more D, up to fully deuterated; alternatively, R 6 is methyl or -CD 3 ; R t is H, D or halogen; alternatively, R t is H, D or F; Y 2 is O or S; R 16 and R 17 are independently H, D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more R"; alternatively, R 10 is H, D, C 1-3 alkyl or C 1-3 haloalkyl, wherein the C 1-3 alkyl and C 1-3 haloalkyl are optionally substituted with one or more D, up to fully deuterated; or, R 16 , R 17 and the atom to which they are attached are taken together to form C 3-6 cycloalkyl, which is optionally substituted with one or more R"; alternatively, R 16 , R 17 and the atom to which they are attached are taken together to form cyclohexyl, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form 3- to 7-membered monocyclic heterocyclyl, which is optionally substituted with one or more R"; alternatively, R 16 , R 17 and the atom to which they are attached are taken together to form 6-membered heterocyclyl having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form 6- to 12-membered fused bicyclic heterocycle, which is optionally substituted with one or more R"; alternatively, R 16 , R 17 and the atom to which they are attached are taken together to form 8- to 10-membered fused bicyclic heterocycle having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form C 6-10 aryl, which is optionally substituted with one or more R"; alternatively, R 16 , R 17 and the atom to which they are attached are taken together to form phenyl, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form 5- to 10-membered heteroaryl, which is optionally substituted with one or more R"; alternatively, R 16 , R 17 and the atom to which they are attached are taken together to form 6-membered heteroaryl having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; each R" is independently D, -C(O)OR g , -C(O)NR h R j , -NR g C(O)R h , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more D, up to fully deuterated; alternatively, each R" is independently D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated.
  20. The compound according to claim 1 or 2, or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein the compound is a compound of formula (IV-1): wherein, R 5 is halogen; alternatively, R 5 is F; R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with one or more D, up to fully deuterated; alternatively, R 6 is methyl or -CD 3 ; R t is H, D or halogen; alternatively, R t is H, D or F; Y 2 is O or S; R 16 , R 17 and the atom to which they are attached are taken together to form C 3-6 cycloalkyl, which is optionally substituted with one or more R"; alternatively, R 16 , R 17 and the atom to which they are attached are taken together to form cyclohexyl, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form 3- to 7-membered monocyclic heterocyclyl, which is optionally substituted with one or more R"; alternatively, R 16 , R 17 and the atom to which they are attached are taken together to form 6-membered heterocyclyl having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form 6- to 12-membered fused bicyclic heterocycle, which is optionally substituted with one or more R"; alternatively, R 16 , R 17 and the atom to which they are attached are taken together to form 8- to 10-membered fused bicyclic heterocycle having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form C 6-10 aryl, which is optionally substituted with one or more R"; alternatively, R 16 , R 17 and the atom to which they are attached are taken together to form phenyl, which is optionally substituted with one or more R"; or R 16 , R 17 and the atom to which they are attached are taken together to form 5- to 10-membered heteroaryl, which is optionally substituted with one or more R"; alternatively, R 16 , R 17 and the atom to which they are attached are taken together to form 6-membered heteroaryl having 1 or 2 ring heteroatoms N, which is optionally substituted with one or more R"; each R" is independently D, -C(O)OR g , -C(O)NR h R j , -NR g C(O)R h , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl or 3- to 7-membered heterocyclyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl and 3- to 7-membered heterocyclyl are optionally substituted with one or more D, up to fully deuterated; alternatively, each R" is independently D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated; wherein each of R g , R h and R j is independently H, D, C 1-6 alkyl or C 1-6 haloalkyl, wherein the C 1-6 alkyl and C 1-6 haloalkyl are optionally substituted with one or more D, up to fully deuterated.

Description

This application claims the priority of Chinese application No. 202310806589.3, filed on July 3, 2023, which is incorporated herein by reference in its entirety. TECHNICAL FIELD The present disclosure belongs to the technical field of medicine, and particularly relates to a highly selective compound which has an inhibitory effect on Bruton's tyrosine kinase (BTK) and its drug resistance mutation, a pharmaceutical composition comprising the same, and a preparation method and use thereof. BACKGROUND Bruton's tyrosine kinase belongs to the Tec family of cytoplasmic tyrosine kinases, which is the second largest family of non-receptor kinases in human. It is expressed in all cell lineages of hematopoietic system (except T cells), and it is located in bone marrow, spleen and lymph nodes tissues. Inactive mutations in the gene encoding Btk lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (XID) in mice. These two diseases are characterized by major defects in the development and function of B cells, indicating that Btk plays a vital role in the development and function of B cells. In addition, the constitutive activation of Btk in B cells leads to the accumulation of autoreactive plasma cells. Preclinical studies have shown that Btk-deficient mice are resistant to the development of collagen-induced arthritis. In addition, the clinical study of Rituxan (a CD20 antibody that exhausts mature B cells) have revealed the key role of B cells in many inflammatory diseases (such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis). Moreover, the abnormal activation of Btk plays an important role in the pathogenesis of B-cell lymphoma, indicating that the inhibition of Btk can be used to treat hematological malignancies. Ibrutinib, a covalent Btk inhibitor, has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM) and chronic graft-versus-host disease (cGVHD). Despite its excellent efficacy and general tolerance, adverse events such as bleeding, rash and diarrhea have been reported. These adverse reactions related to ibrutinib are thought to be mainly related to the off-target effect of ibrutinib, which has been proved to be associated with the inhibition of EGFR and Tec. Targeting EGFR can induce significant skin toxicity and gastrointestinal adverse reactions, because EGFR signaling cascade involves the biology of skin and gastrointestinal system. Both Btk and Tec belong to Tec family kinases. Platelets express Btk and Tec, which serve the downstream of glycoprotein VI(GPVI) signaling. Tec compensates for the loss of Btk in the downstream signaling of GPVI in rat platelets. The inhibition of Tec kinase by ibrutinib interferes with platelet aggregation and may contribute to the observed bleeding. Therefore, Btk inhibitors with high Btk inhibition and low EGFR and Tec inhibition are needed to reduce or avoid bleeding, rash and diarrhea. Ibrutinib also irreversibly binds to interleukin-2-inducible tyrosine kinase (ITK). ITK plays a key role in the natural killer function of NK cells stimulated by FcR, primarily through antibody-dependent NK cell-mediated cytotoxicity (ADCC). ADCC is the standard of treatment for B-cell malignancies today, so it is desirable to have a Btk inhibitor that has high Btk inhibition and low ITK inhibition. Covalent (irreversible) BTK inhibitors specifically target the cysteine residue C481 within BtK. After treatment with ibrutinib, primary and secondary drug resistance occurred. Mutations in BTK such as C481S, C481Y, C481R and C481F have been proved to clearly interfere with drug binding. It is predicted that the observed incidence of drug resistance will increase when clinical use goes on over time. Non-covalent (reversible) BTK inhibitors do not need to bind to the C481 residue of BTK to effectively inhibit the wild-type and mutant BTK with the C481 residue replaced. However, existing literature has reported that non-covalent BTK inhibitors can also have acquired drug resistance mutations, such as V416L, A428D, M437R, T474I, and L528W mutations. Therefore, it is necessary to develop new BTK inhibitors. SUMMARY The present disclosure provides a novel 1H-pyrazolo[4,3-c]pyridine compound, a composition comprising the compound, and use thereof, wherein the compound has better inhibitory activity on BTK, C481 mutated BTK, and V416L, A428D, M437R, T474I, or L528W mutanted BTK kinases, higher selectivity compared with EGFR, TEC, and ITK kinases, and better pharmacodynamic and/or pharmacokinetic properties, and can treat a BTK kinase-mediated disease or condition. In this regard, the present disclosure adopts the following technical solutions: In one aspect, the present disclosure relates to a compound of formula (A), or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solv